Form 4: Haemonetics EVP & General Counsel Reports Significant Stock Acquisition from Performance Share Vesting

Michelle L. Basil, EVP and General Counsel of Haemonetics Corp, reported the acquisition of 15,554 shares from a performance share unit award and the subsequent disposition of 7,469 shares for tax obligations.

Summary

• Michelle L. Basil, EVP and General Counsel of Haemonetics Corp (HAE), acquired 15,554 shares of common stock on May 30, 2025, resulting from the vesting of a performance share unit (PSU) award.
• The PSU award was granted on May 16, 2022, and its vesting was based on the company's total shareholder return relative to the S&P MidCap 400 Index over a performance period ending May 15, 2025.
• Concurrently, 7,469 shares were disposed of at a price of $69.38 per share to cover tax obligations related to the PSU vesting.
• Following these transactions, Ms. Basil's beneficial ownership stands at 42,252 shares, which includes previously reported unvested restricted stock units (RSUs).

Sentiment

Score: 7

Explanation: The document reports a routine executive compensation event where performance targets were met, leading to stock vesting. While some shares were sold for taxes, this is standard. It reflects positively on the company's performance relative to its benchmark, but does not provide new strategic or financial insights beyond this.

Positives

• The vesting of 15,554 performance share units indicates that Haemonetics Corp met its performance targets relative to the S&P MidCap 400 Index over the specified period.
• The acquisition of shares by a key executive aligns their interests with shareholders.

Negatives

• A portion of the acquired shares (7,469 shares) was immediately sold to cover tax obligations, which is a common practice but reduces the executive's direct ownership post-vesting.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook. It solely reports past insider transactions.

Industry Context

This filing reflects a routine executive compensation event within the healthcare technology or medical device industry, where performance-based equity awards are common. The use of the S&P MidCap 400 Index as a benchmark is a standard practice for aligning executive incentives with broader market performance.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) tied to relative Total Shareholder Return (TSR) against an index like the S&P MidCap 400 is a common and widely accepted practice in executive compensation across various industries, including healthcare technology.
• Companies such as Medtronic (MDT), Boston Scientific (BSX), or Stryker (SYK) often utilize similar long-term incentive structures for their executives, linking compensation to stock performance and strategic goals.
• The immediate disposition of shares to cover tax obligations upon vesting is also a standard and expected practice for equity compensation.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates the company met performance targets, which is generally positive for shareholder value. The executive's continued ownership aligns interests.

Key Dates

Recommendation

Keywords

Haemonetics Corp, HAE, Form 4, Insider Trading, Stock Ownership, Performance Share Units, PSU, Restricted Stock Units, RSU, Executive Compensation, Michelle L. Basil